DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement
November 13, 2024 17:45 ET
|
DiagnaMed Holdings Corp.
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...
DiagnaMed Expands with Drug and Clinical Research AI Platform
August 21, 2024 08:00 ET
|
DiagnaMed Holdings Corp.
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for...
DiagnaMed Cancels Previously Announced Private Placement
July 03, 2024 16:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...
DiagnaMed Announces Appointment of New Director
February 13, 2023 07:15 ET
|
Diagnamed Holdings Corp.
TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, announced today that Ms. Emily Davis resigned...
DiagnaMed Holdings Announces Listing on the Canadian Securities Exchange
November 08, 2022 07:45 ET
|
Diagnamed Holdings Corp.
Focusing on novel AI-based digital diagnostics and therapeutics solutions for brain health Developing BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an...